A DRAMATIC RESPONSE TO DENOSUMAB: PROTRACTED HYPOCALCEMIA RELATED TO HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE 1-ASSOCIATED ADULT T-CELL LEUKEMIA/LYMPHOMA.
| Autor: | Japp EA, Meron MK, Zonszein J |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | AACE clinical case reports [AACE Clin Case Rep] 2019 Apr 25; Vol. 5 (3), pp. e210-e213. Date of Electronic Publication: 2019 Apr 25 (Print Publication: 2019). |
| DOI: | 10.4158/ACCR-2018-0479 |
| Abstrakt: | Objective: Adult T-cell leukemia/lymphoma (ATL) is known for its aggressive behavior, frequently presenting with hypercalcemia. ATL tumor cells uniquely secrete parathyroid hormone-related protein, viral peptides, and inflammatory cytokines, inducing a state of high bone turnover and activation of the receptor activator of nuclear factor kappa-B signaling pathway resulting in hypercalcemia. Methods: A 54-year-old woman diagnosed with ATL presented with severe hypercalcemia refractory to bisphosphonate therapy. Treatment with denosumab was followed by protracted hypocalcemia and hypophosphatemia lasting approximately 5 months. Results: Hypercalcemia due to acute ATL was responsive in this case to denosumab therapy. Conclusion: Clinicians should be aware of the possibility of protracted hypocalcemia in patients with ATL exposed to denosumab therapy. Competing Interests: DISCLOSURE Dr. Joel Zonszein is on the advisory board of Novo Nordisk, the advisory board and speakers bureau of Boehringer Ingelheim, and the advisory board and speakers bureau of AstraZeneca. The other authors have no multiplicities of interest to report. (Copyright © 2019 AACE.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|